New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTripeptide-29 vs SS-31 (Elamipretide)

Tripeptide-29 vs SS-31 (Elamipretide)

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Tripeptide-29
Anti-Aging & Longevity
SS-31 (Elamipretide)
Summary
Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
Half-Life
Not applicable (topical)
~2–5 hours
Admin Route
Topical
SubQ
Research
Typical Dose
0.01-0.1% in formulation
5–10 mg
Frequency
Once or twice daily
Daily to several times per week
Key Benefits
  • Stimulates fibroblast collagen synthesis via damage-signal mechanism
  • Reduces fine lines and improves skin smoothness
  • Supports dermal matrix integrity
  • Naturally bioidentical to collagen fragment sequences
  • Well-tolerated in all skin types
  • Synergistic with copper peptides and retinoids
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
Side Effects
  • Excellent tolerability profile
  • No documented significant adverse effects at cosmetic concentrations
  • Rare sensitivity reactions in individuals with peptide allergies
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
Stacks With